Reuters
- Shares of Sorrento Therapeutics spiked as much as 244% on Friday after the company claimed an antibody it’s developing showed 100% inhibition of the COVID-19 virus in preclinical studies.
- The small biotechnology company said it aims to create an antibody cocktail that would act as a “protective shield” against coronavirus.
- Sorrento said full results of its antibody candidate will be submitted to a peer-reviewed publication shortly.
- Visit Business Insider’s homepage for more stories.
Sorrento Therapeutics skyrocketed as much as 244% on Friday after the company claimed an antibody it’s developing showed 100% inhibition of the COVID-19 virus in preclinical studies.
The small biotechnology company plans to “generate an antibody cocktail product that would act as a ‘protective shield’ against SARS-CoV-2 coronavirus.”
Sorrento said it will ask regulators for priority evaluation and an accelerated review of its drug candidate.
The company hopes to receive government support and partner with a pharmaceutical company to scale up manufacturing of its coronavirus candidate, if proven successful.
Despite the positive data claims from the company, the antibody has yet to be submitted to a peer-reviewed publication, according to Sorrento.
Sorrento’s market value surged from $549 million at yesterday’s close to roughly $1.9 billion at Friday’s intraday highs.
Markets Insider
Leave a Reply
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
